[ad_1]
While reporting financial results for the third quarter on Friday, diabetes management company Embecta Corp. (EMBC), which was spun-off from medical technology company Becton, Dickinson and Co. (BDX), raised its adjusted earnings guidance for the full-year 2025, while tightening annual revenue outlook range.
For fiscal 2025, the company now projects adjusted earnings in a range of $2.90 to $2.95 per share on revenues between $1.078 billion and $1.085 billion.
Previously, the company expected adjusted earnings in a range of $2.70 to $2.90 per share on revenues between $1.073 billion and $1.090 billion.
On average, four analysts polled expect the company to report earnings of $2.83 per share on revenues of $1.08 billion for the year. Analysts’ estimates typically exclude special items.
Separately, the Company’s Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock, payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
[ad_2]
Source link